AzTrials
AzTrials

Post Traumatic Stress DisorderNCT02915497

Early Prevention of PTSD in Patients Within One Week of Acute Physical Trauma

A study testing Abbreviated Early Prolonged Exposure Therapy in people with Post Traumatic Stress Disorder, run by Sunnybrook Health Sciences Centre at 1 site in Canada.

Suspended

Paused. Enrolment is on hold for now and may resume.

Official record
Search all trials

Trial summary

The objective of this study is to assess the feasibility and effectiveness of AEPET plus Resilience Based Therapy (RBT) versus RBT alone for the prevention of PTSD and depression in trauma patients. Read more about this study

Who is it for?
Ages 17 to 75 years
Conditions the study is for
Post Traumatic Stress Disorder
What is being tested?
Abbreviated Early Prolonged Exposure Therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteCanada
Study dates
Feb 2016to Aug 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 17 to 75 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Age 17-75
  • Experienced an acute physical trauma in the past 4 days where the patient believed it was potentially life-threatening in their mind at the time of the trauma
  • Have some clear memories of the trauma
  • Contain any risk factors for PTSD
  • An abbreviated Injury Severity (AIS) score of 1-3 (Minor, Moderate and Severe; not life threatening)

Who cannot join

  • Inability to communicate sufficiently in English to be able to complete questionnaires and provide informed consent
  • A diagnosis of psychosis, mental retardation or autism
  • Blood alcohol level of >0.08mmol/L (25 mg/dl) at time of admission
  • Cognitive impairment apparent on interview/collateral from trauma team
  • Severe head injury
  • Withdrawal Criteria
Show all 9Show fewer
  • If the patient is thought to be at risk to self or others, or be in need of immediate psychiatric assessment, in which case the patient will be referred urgently for assessment with psychosocial oncology or department of psychiatry
  • If the patient wishes to discontinue the study
  • If the patient is noted to be cognitively impaired during the course of the study such that he/she cannot complete a questionnaire reliably or physically impaired such that it is too burdensome for the patient to complete the questionnaire package.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, M4N 3M5

Other trials in Canada

About this study

Official title: A Pilot Randomized Controlled Trial in Patients Within One Week of Acute Physical Trauma to Test the Feasibility and Effectiveness of AEPET Plus RBT Versus RBT Alone for the Prevention of PTSD and Depression

The objective of this study is to assess the feasibility and effectiveness of AEPET plus Resilience Based Therapy (RBT) versus RBT alone for the prevention of PTSD and depression in trauma patients. The intervention group who have AEPET plus RBT will have reduced level of post traumatic stress symptoms and depression post sessions as well as reduced symptoms of PTSD and depression at 4- 6 weeks as compared to the control group who have -"Resilience Based" less specific supportive therapy.

Read the detailed description

Background:

The Sunnybrook Health Sciences Centre contains one of the largest trauma centers in Canada, treating approximately 1,100 patients annually. Many of these cases typically include unexpected events that can cause severe or life-threatening injuries and at the time patients often experience horror and helplessness and even threat of death. Many of these traumatic injuries are not only physically damaging but psychologically as well. Lower psychological well-being has been reported in trauma survivors, specifically symptoms related to Depression and Post Traumatic Stress Disorder (PTSD).

Methods:

Patients in trauma units admitted within the previous week will be approached by a trauma team member to see if they are willing to be approached by a Research Assistant (RA). If they agree, an RA will seek permission to screen for eligibility and complete recruitment and the informed consent process. Patients will be recruited if they have a premorbid risk factor for PTSD or if their current trauma resulted in clear memories of it being life threatening and horrifying to them or resulted in dissociation. Participants will be excluded if they were intoxicated at the time of the trauma, they seem cognitively impaired or if they suffered a severe head injury.

After stratified 1:1 randomization to either AEPET plus RBT (n=10-15) or RBT alone (n=10-15) , consenting participants will complete baseline measures and 3 therapy sessions, starting within 1 week post-trauma. Participants will be scheduled for their first 30-60 minute therapy session at consent . Participants will receive two more face-to-face / telephone sessions as close together as possible, followed by completing three questionnaires after the second session.

In the protocol, participants will give consent within 1 week post-trauma. Eligible participants will be recruited if they are expected to remain in hospital for a minimum of 1 day to be able to complete 1 of the 3 sessions. If a patient is discharged before the second or third / final therapy session, they will be phoned for two or one remaining sessions, respectively.

Participants will be included as 'treated' in the data analysis if they complete 2 out of the 3 therapy treatments.

TAU will include routine psychosocial care, psychological management of trauma patients, including brief assessment and referral to psychiatry if the trauma team thinks it's necessary. RBT will specifically address the five essential intervention principles for the psychosocial management of trauma which include promotion of safety, self-efficacy, calming, connectedness and hope.

The following questionnaires will be administered to patients in both the control and intervention group at baseline,

  1. Stanford Acute Stress Reaction Questionnaire (SASRQ)
  2. Posttraumatic Cognitions Inventory (PTCI)
  3. Beck Depression Inventory II (BDI-II)

The following questionnaires will be administered to patients in both the control and intervention group at baseline, with instructions to complete after their second therapy session:

  1. Stanford Acute Stress Reaction Questionnaire (SASRQ)
  2. Posttraumatic Cognitions Inventory (PTCI)
  3. Beck Depression Inventory II (BDI-II)

The following questionnaire will be administered by phone (1,2) and sent by mail (3, 4) to patients one month post enrollment in the study:

  1. (by phone) Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
  2. (by phone) PTSD Symptom Scale interview (PSSI)
  3. (by mail) Posttraumatic Cognitions Inventory (PTCI)
  4. (by mail) Beck Depression Inventory II (BDI-II)

Planned Data Analysis:

Data will be analyzed using SAS. Descriptive statistics will be calculated for all variables. Bivariate comparisons of variables will be made using χ2, Spearman and Pearson correlation coefficients, Student t tests and ANOVA. Stepwise multivariable regression analyses will be undertaken to examine significant correlates of PTSD and between group (control and intervention) differences in all the outcomes. Statistical tests will be two tailed with alpha set at 0.05.

The anticipated outcomes include lower levels of PTSD and depressive symptoms for those having AEPET + RBT vs. RBT alone by self report and by semi structured interview at 4-6 weeks.

Significance:

In testing the feasibility and effectiveness of AEPET as a novel treatment for the prevention of PTSD within its trauma ward, Sunnybrook Hospital would potentially pioneer a feasible and cost-effective method for employing a quicker response, targeted treatment for mitigating symptoms of PTSD and depression after trauma.

Being tested
Abbreviated Early Prolonged Exposure Therapy
Keywords
Prolonged Exposure Therapy
Medical subject headings
Stress Disorders, Post-Traumatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Abbreviated Early Prolonged Exposure TherapyBehavioural

    Since many trauma patients are discharged within 4 weeks, AEPET with the same length (45 minutes - 1 hour) and number of sessions as PET, is given in a shorter time period (daily for 3 days as opposed to weekly over 3 weeks).

Study groups in NCT02915497
Study groupRoleWhat they receive
Treatment As Usual + Resilience-Based Supportive TherapyNo interventionRoutine psychosocial management of trauma patients, including Manualized Resilience-Based Therapy.
Abbreviated Early Prolonged Exposure TherapyExperimentalAEPET, including Manualized Resilience-Based supportive Therapy.
Receives: Behavioral: Abbreviated Early Prolonged Exposure Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. PTSD Presence and Severity at 1 month follow-up

    Scale used to assess presence and measure severity: The Post-Traumatic Stress Disorder (PTSD) Symptom Scale -Interview (PSS-I)

    Measured: 1 - 2 Months

Secondary outcomes (4)
  1. Change from Baseline Trauma-related Thoughts and Beliefs at Therapy Time-Point 2 and 1 month follow-up

    Scale used to measure Trauma-related Thoughts and Beliefs: The Posttraumatic Cognitions Inventory (PTCI)

    Measured: 1 - 2 Months

  2. Change from Baseline Depresssive Symptoms at Therapy Time-Point 2 and 1 month follow-up

    Scale used to measure Depressive Symptoms: Beck Depression Inventory II (BDI-II)

    Measured: 1 - 2 Months

  3. PTSD Presence and Severity and Diagnosis at 1 month follow-up

    Scale used to assess presence and measure severity of PTSD: The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)

    Measured: 1 - 2 Months

  4. Psychological Well-being at 1 month follow-up

    Scale used to measure Psychological Well-being: The Stanford Acute Stress Reaction Questionnaire (SASRQ)

    Measured: 1 - 2 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Sep 2016 (estimated)
  2. Study startFeb 2016
  3. Primary completionAug 2023
  4. Study completionAug 2025 (estimated)

Why it stopped: Preliminary data analysis underway, will determine whether additional recruitment is necessary upon review of collected data.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02915497
Sponsor's protocol ID
411-2014
Status last verified
Dec 2024
First submitted
14 Jul 2016
Last updated
5 Dec 2024
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Abbreviated Early Prolonged Exposure Therapy in people with Post Traumatic Stress Disorder, run by Sunnybrook Health Sciences Centre at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: paused, as of the sponsor's last update on 5 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

PTSD Presence and Severity at 1 month follow-up (time frame: 1 - 2 Months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in